About

A seasoned team experienced in developing cancer medicines to create a fully integrated oncology company.

PRT2527, a Novel, Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Models of Lymphoid Malignancies

Neha Bhagwat, Bruce Ruggeri, Yang Zhang, YaronMosesson, Clare Killick-Cole, Veena Jagannathan, Peggy Scherle